Pfizer (NYSE:PFE) received a $40.00 price objective from research analysts at Societe Generale in a research report issued on Wednesday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Societe Generale’s price target points to a potential upside of 7.99% from the company’s previous close.
PFE has been the topic of several other reports. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. JPMorgan Chase & Co. set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group set a $39.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, November 16th. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Finally, Morgan Stanley set a $41.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the stock. Pfizer has an average rating of “Hold” and a consensus target price of $39.14.
Pfizer (NYSE:PFE) traded down $0.76 during midday trading on Wednesday, hitting $37.04. The company had a trading volume of 34,016,593 shares, compared to its average volume of 19,660,000. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer has a 52-week low of $30.93 and a 52-week high of $39.43. The firm has a market cap of $220,780.00, a P/E ratio of 10.52, a price-to-earnings-growth ratio of 2.40 and a beta of 1.01.
Pfizer announced that its board has initiated a stock repurchase program on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.
In other news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now directly owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Shine Investment Advisory Services Inc. purchased a new position in Pfizer in the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer in the 2nd quarter valued at about $103,000. D. Scott Neal Inc. lifted its stake in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Herndon Capital Management LLC purchased a new position in Pfizer in the 2nd quarter valued at about $120,000. Finally, Americafirst Capital Management LLC purchased a new position in Pfizer in the 3rd quarter valued at about $127,000. 69.87% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Pfizer (PFE) Given a $40.00 Price Target at Societe Generale” was first published by American Market News and is the property of of American Market News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/31/pfizer-pfe-given-a-40-00-price-target-at-societe-generale.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
